Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PRF1
REST API REST API
Homo sapiens
PRF1 is differentially expressed in 240 experiments: 97 organism parts: bone marrow, lung, ... (95 more);, 189 disease states: normal, colorectal adenocarcinoma, ... (187 more);, 97 cell types 173 cell lines 28 compound treatments and 65 other conditions.
Synonyms P1, HPLH2, PFP
Orthologs PRF1 (5 of 6) (Danio rerio)   PRF1 (3 of 6) (Danio rerio)   PRF1 (2 of 6) (Danio rerio)   PRF1 (4 of 6) (Danio rerio)   Prf1 (Mus musculus)   PRF1 (6 of 6) (Danio rerio)   PRF1 (1 of 6) (Danio rerio)   PRF1 (Gallus gallus)   Q69GU5_BOVIN (Bos taurus)   Prf1 (Rattus norvegicus)   ENSXETG00000012994 (Xenopus laevis)   prf1 (Xenopus laevis)   LOC100491518 (Xenopus laevis)   LOC100492973 (Xenopus laevis)   LOC100493300 (Xenopus laevis)   LOC100489487 (Xenopus laevis)   ENSXETG00000027891 (Xenopus laevis)   LOC100493140 (Xenopus laevis)   LOC100489324 (Xenopus laevis)   PRF1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term defense response to virus, plasma membrane, cytolysis, protein binding, apoptosis, protein homooligomerization, extracellular region, cytoplasmic membrane-bounded vesicle, endosome, integral to membrane, circadian rhythm, response to ethanol, cellular defense response, calcium ion binding, endosome lumen, immune response to tumor cell, cytolytic granule, defense response to tumor cell, wide pore channel activity
InterPro Term C2_Ca-dep, C2_membr_targeting, MACPF
Gene-Disease Assocation LYMPHOMA, NON-HODGKIN, FAMILIAL, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 2; FHL2
UniProt Accession P14222
Search EB-eye ENSG00000180644
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MEXP-1251, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (29 experiments)

Factor Value U/D Experiments
SW480
4
E-MTAB-37, E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
SR
2
E-MTAB-37, E-MTAB-62
HL-60
1
2
E-GEOD-24147, E-MTAB-37, E-GEOD-5258
HCT8
1
E-MTAB-37
Caki2
1
E-MTAB-37
NCIH1975
1
E-MTAB-37
167 more value(s).


Cell type

studied in E-MEXP-1242, E-TABM-40, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (39 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-GEOD-6740, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
mononuclear cell
1
E-GEOD-7307
liver cancer
1
E-GEOD-21154
HLA-DR negative T-cell
1
E-GEOD-6338
91 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (53 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-MTAB-62, E-GEOD-995, E-GEOD-1729
lung adenocarcinoma
1
3
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
control
1
3
E-GEOD-16363, E-GEOD-8121, E-GEOD-21912, E-GEOD-20602
glioblastoma
2
E-GEOD-4290, E-MTAB-62
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
chronic lymphocytic leukemia
2
E-GEOD-2466, E-MTAB-37
183 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-6907, E-GEOD-3720, E-GEOD-5824, ... (23 experiments)

Factor Value U/D Experiments
none
3
5
E-MEXP-1958, E-GEOD-412, E-GEOD-5824, E-GEOD-995, E-GEOD-7400, ... (8 experiments)
baseline sevoflurane
1
E-GEOD-4386
vanadium pentoxide
1
E-GEOD-5339
interferon alpha
1
E-GEOD-1740
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
anti-CD3 + anti-CD28
1
E-GEOD-7307
22 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
70
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-22513, E-MEXP-1251, E-GEOD-19246, E-GEOD-21374, ... (14 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-3140, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-GEOD-2509, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-7011, E-GEOD-20847, E-MTAB-108

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-MEXP-149, E-GEOD-2466, E-GEOD-17476, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20540, E-MEXP-1446, E-GEOD-22278, E-GEOD-20505

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (29 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-980

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-33562, E-GEOD-21909

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-TABM-43, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-3494

Processing time: 0.409 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM